Company news
MIRA Pharmaceuticals, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
October 27, 2024
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
October 20, 2024
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
September 26, 2024
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
September 18, 2024
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
September 17, 2024
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
September 10, 2024
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Study
August 27, 2024
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
August 25, 2024
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
August 18, 2024
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite, Nor-Ketamir a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
August 13, 2024
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
August 11, 2024
MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year
July 28, 2024
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action
July 26, 2024
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
July 24, 2024
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
July 21, 2024
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
July 14, 2024
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing
June 23, 2024
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
June 9, 2024
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
May 28, 2024
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
May 19, 2024
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
April 1, 2024
MIRA Pharmaceuticals Provides Corporate Update
February 4, 2024
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
December 3, 2023
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
November 28, 2023
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11: 30 a.m. Eastern Time
November 20, 2023
MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
November 20, 2023
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
November 19, 2023
MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot
September 17, 2023
MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1: 00 p.m. Eastern Time
August 28, 2023
Decks
- Investor Presentation (October 2026)
Investor deck · 30 slides · October 2026
- Investor Presentation (April 2026)
Investor deck · 56 slides · April 2026
- Investor Presentation (June 2025)
Investor deck · 36 slides · June 2025